Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Deutsche Bank Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $8

Author: Benzinga Newsdesk | December 12, 2023 05:30am
Deutsche Bank analyst Neena Bitritto-Garg initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and announces Price Target of $8.

Posted In: ABOS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist